A man walks past an electronic stock board displaying a graph. (Photographer: Tomohiro Ohsumi/Bloomberg)
Shares of Syngene International Ltd. have surged nearly threefold in the last six months, beating all benchmarks and peers, as the contract researcher signed pacts to make a drug used in severe cases of Covid-19, scaled up capacity and added clients.The stock now trades at a record of Rs 597 apiece, rising 190% since the global equity selloff triggered by the pandemic in March. That compares with a twofold jump in the Nifty Pharma In...